Study Reveals No Link Between HDL Cholesterol and Movement Disorders
FRIDAY, Sept. 20, 2024 – There is no correlation between high-density lipoprotein cholesterol (HDL-C) levels and a patient's risk for developing movement disorders while taking an antipsychotic, according to a study published in the April-June issue of Innovations in Clinical Neuroscience.
Carolyn O’Donnell, Pharm.D., from the Edward Hines Jr. Veterans Administration Hospital in Hines, Illinois, and colleagues investigated associations between patients taking antipsychotics with low HDL-C and the risk for developing a movement disorder. The analysis included 89 adult patients at an inpatient state psychiatric facility.
The researchers report that only eight patients had an Abnormal Involuntary Movement Scale score greater than 0 and HDL-C levels ranged from 17 mg/dL to 83 mg/dL. There was no statistically significant association seen when comparing a patient's movement disorder, Abnormal Involuntary Movement Scale scores, and HDL-C levels.
"It is our hope that our research will support prioritized prescribing decisions focused more directly on removing offending medications, versus exploring hypothesized physiologic factors such as HDL-C, because earlier recognition of drug-induced movement disorders permits rapid intervention and decreased risk of permanently disfiguring and debilitating extrapyramidal symptoms," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
2010 to 2019 Saw Global Decline in Noncommunicable Disease Mortality
FRIDAY, Sept. 12, 2025 -- Noncommunicable disease (NCD) mortality decreased in most countries around the world from 2010 to 2019, according to a study published online Sept. 10 in...
No Adverse Neurodevelopmental Effects Seen From Inhaled Anesthesia in Children Under 2
THURSDAY, Sept. 11, 2025 -- For children younger than 2 years undergoing surgery, no adverse neurodevelopmental effects are seen with the addition of dexmedetomidine and...
Dementia Odds Significantly Increase With More Psychiatric Comorbidities
WEDNESDAY, Sept. 10, 2025 -- Dementia odds significantly increase with the number of psychiatric comorbidities, according to a study published online Sept. 9 in BMJ Mental...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.